Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Phase 3 Open-Label Study of Recombinant von Willebrand Factor Prophylaxis in Severe von Willebrand Disease
2016-001478-14Phase 3Completed
- Sponsor
- Baxalta
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Baxalta. Started Nov 2016; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2016-001478-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001478-14.